JP2018538273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538273A5 JP2018538273A5 JP2018526571A JP2018526571A JP2018538273A5 JP 2018538273 A5 JP2018538273 A5 JP 2018538273A5 JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018538273 A5 JP2018538273 A5 JP 2018538273A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- combination
- composition
- alkoxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 229960000265 cromoglicic acid Drugs 0.000 claims description 6
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 210000003630 histaminocyte Anatomy 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 0 C**(C*)*1C(*C(C=*)=C(C(C=C(C2C(C*=C)C2)C2=C)=*)C2=C[C@](C)*)C1 Chemical compound C**(C*)*1C(*C(C=*)=C(C(C=C(C2C(C*=C)C2)C2=C)=*)C2=C[C@](C)*)C1 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258882P | 2015-11-23 | 2015-11-23 | |
| US62/258,882 | 2015-11-23 | ||
| PCT/US2016/063462 WO2017091644A1 (en) | 2015-11-23 | 2016-11-23 | Compositions and methods for treating ischemic stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538273A JP2018538273A (ja) | 2018-12-27 |
| JP2018538273A5 true JP2018538273A5 (enExample) | 2020-01-09 |
Family
ID=58764360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526571A Pending JP2018538273A (ja) | 2015-11-23 | 2016-11-23 | 虚血性脳卒中を処置するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180344682A1 (enExample) |
| EP (1) | EP3380095B1 (enExample) |
| JP (1) | JP2018538273A (enExample) |
| KR (1) | KR20180081812A (enExample) |
| CN (1) | CN108472275A (enExample) |
| AU (1) | AU2016359674A1 (enExample) |
| CA (1) | CA3005909A1 (enExample) |
| MX (1) | MX390748B (enExample) |
| WO (1) | WO2017091644A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| KR20190044647A (ko) | 2016-08-31 | 2019-04-30 | 더 제너럴 하스피탈 코포레이션 | 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포 |
| EP3654946A4 (en) | 2017-07-20 | 2021-04-21 | AZTherapies, Inc. | CROMOLYNE SODIUM AND IBUPROFEN POWDER FORMULATIONS |
| AU2017442079A1 (en) * | 2017-12-04 | 2020-06-25 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CA3096545A1 (en) * | 2018-04-09 | 2019-10-17 | The General Hospital Corporation | Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders |
| CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
| CA3122989A1 (en) | 2018-12-10 | 2020-06-18 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| JP2023520580A (ja) | 2020-04-06 | 2023-05-17 | ザ ジェネラル ホスピタル コーポレイション | コロナウイルス誘発炎症状態の処置方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1601380A1 (en) * | 2003-02-13 | 2005-12-07 | Licentia OY | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| EP1789057B1 (en) * | 2004-08-30 | 2010-02-24 | Seo Hong Yoo | Neuroprotective effect of solubilized udca in focal ischemic model |
| CA2751125C (en) * | 2009-01-29 | 2017-06-20 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US9925282B2 (en) * | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| MX2011009362A (es) * | 2009-03-05 | 2011-09-26 | Abbott Lab | Proteinas de union a il-17. |
| JP2012520311A (ja) * | 2009-03-11 | 2012-09-06 | プレキシコン インコーポレーテッド | Ｒａｆキナーゼの阻害のためのピロロ［２，３−ｂ］ピリジン誘導体 |
| EP2911664B1 (en) * | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| MX381503B (es) * | 2013-05-23 | 2025-03-12 | Aztherapies Inc | Métodos para la liberación de cromolina. |
| AU2014340182B2 (en) * | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| WO2015120389A1 (en) * | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| KR20190044647A (ko) * | 2016-08-31 | 2019-04-30 | 더 제너럴 하스피탈 코포레이션 | 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포 |
-
2016
- 2016-11-23 WO PCT/US2016/063462 patent/WO2017091644A1/en not_active Ceased
- 2016-11-23 AU AU2016359674A patent/AU2016359674A1/en not_active Abandoned
- 2016-11-23 MX MX2018006390A patent/MX390748B/es unknown
- 2016-11-23 EP EP16869210.1A patent/EP3380095B1/en not_active Not-in-force
- 2016-11-23 JP JP2018526571A patent/JP2018538273A/ja active Pending
- 2016-11-23 US US15/777,062 patent/US20180344682A1/en not_active Abandoned
- 2016-11-23 CA CA3005909A patent/CA3005909A1/en active Pending
- 2016-11-23 KR KR1020187017549A patent/KR20180081812A/ko not_active Withdrawn
- 2016-11-23 CN CN201680075914.1A patent/CN108472275A/zh active Pending
-
2021
- 2021-06-03 US US17/338,172 patent/US20220125753A1/en not_active Abandoned